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Abstract
Background & Aims—The drug-induced liver injury network (DILIN) is conducting a 
prospective study of patients with DILI in the United States. We present characteristics and 
subgroup analyses from the first 1257 patients enrolled in the study.
Methods—In an observational longitudinal study, we began collecting data on eligible 
individuals with suspected DILI in 2004, following them for 6 months or longer. Subjects were 
evaluated systematically for other etiologies, causes, and severity of DILI.
Results—Among 1257 enrolled subjects with suspected DILI, the causality was assessed in 1091 
patients, and 899 were considered to have definite, highly likely, or probable DILI. Ten percent of 
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patients died or underwent liver transplantation and 17% had chronic liver injury. In the 89 
patients (10%) with pre-existing liver disease, DILI appeared to be more severe than in those 
without (difference not statistically significant; P=.09) and mortality was significantly higher 
(16% vs 5.2%; P<.001). Azithromycin was the implicated agent in a higher proportion of patients 
with pre-existing liver disease compared to those without liver disease (6.7% vs. 1.5%, p=0.006). 
Forty-one cases with latency ≤ 7 days were caused predominantly by antimicrobial agents (71%). 
Two most common causes for 60 DILI cases with latency >365 days were nitrofurantoin (25%) or 
minocycline (17%). There were no differences in outcomes of patients with short vs long latency 
of DILI. Compared to individuals younger than 65 y, individuals 65 y or older (n=149) were more 
likely to have cholestatic injury, although mortality and rate of liver transplantation did not differ. 
Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, 
azithromycin, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin. Four of 
these patients died.
Conclusion—Mortality from DILI is significantly higher in individuals with pre-existing liver 
disease or concomitant severe skin reactions compared to patients without. Further studies are 
needed to confirm the association between azithromycin and increased DILI in patients with 
chronic liver disease. Older age and short or long latencies are not associated with DILI mortality.
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INTRODUCTION
Idiosyncratic drug induced liver injury (DILI) is a rare clinical event but it carries significant 
morbidity and mortality (1–3). Its annual incidence in the general population ranges between 
14 and 19 events per 100,000 inhabitants with nearly 30% exhibiting jaundice (4, 5). It is 
one of the leading causes of acute liver failure in the United States (6, 7) and it continues to 
be an important barrier for new drug development and marketing (8). The Drug Induced 
Liver Injury Network (DILIN), funded by the U.S. National Institutes of Health, is a 
consortium of several academic institutions and its overarching goal is to comprehensively 
investigate all aspects of DILI in both children and adults (9). The DILIN Prospective Study 
is an ongoing undertaking of the DILIN. It is an observational longitudinal study of 
individuals ≥ 2 years of age with suspected DILI (10). Initiated in 2004, this study has led to 
several publications related to DILI (11–15), including a summary of its initial 300 
participants enrolled. The main findings of those studies were (a) antimicrobials and herbal 
or dietary supplements (HDS) were the major causes, (b) acute DILI carried an 8% risk of 
mortality and 13% risk of unresolved or chronic injury at 6 months following onset, and (C) 
acute hepatitis C and E can masquerade as DILI. Since that report, the DILIN Prospective 
Study has continued to enroll subjects, providing an opportunity to further characterize DILI 
in the United States in a large cohort of patients who were carefully followed and assessed 
in a standardized fashion.
The main objectives of this paper are to provide (a) summary description of subjects 
enrolled and their outcomes, (b) more detailed description and characterization of DILI 
caused by major therapeutic classes and individual agents in the United States, and (c) 
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several notable aspects of DILI: like DILI in individuals with preexisting liver disease, in 
older persons, with short and very long latency, and associated with severe cutaneous 
reactions.
METHODS
A detailed description of the DILIN’s enrollment and case ascertainment procedures has 
been published elsewhere (10). Briefly, subjects considered for enrollment into the DILIN 
sign a written informed consent approved by the local institutional review board. Subjects 
are at least 2 years of age at the time of enrollment, and suspected of having experienced 
potential non-acetaminophen DILI within the preceding six months. Criteria for enrollment 
included jaundice (serum bilirubin ≥ 2.5 mg/dL) or coagulopathy (INR > 1.5) with any 
elevations in alanine or aspartate aminotransferase (ALT or AST) alkaline phosphatase (Alk 
P) levels; or, in the absence of jaundice or coagulopathy, elevations of ALT or AST above 5 
times the upper limit of normal (ULN) or Alk P above 2 times ULN. The point at which 
these eligibility criteria were met was used as the definition of onset of hepatotoxicity (as 
opposed to time of onset of symptoms). At the baseline visit, study subjects were queried on 
the chronological use of all drugs and HDS. In addition, relevant clinical, biochemical, 
serological, imaging, and histological data were abstracted from the medical record and, if 
not already done, testing was performed for conditions that can mimic DILI, including 
serology for hepatitis A, B, C and E, CMV, EBV, HSV, and for autoimmune hepatitis. 
Subjects were asked to return for repeated testing at six months; if the serum chemistry 
values or hepatic imaging or examination remained abnormal at that time, the injury was 
regarded chronic, and follow-up was continued with visits at months 12 and 24. This 
information was assembled into a pre-defined dataset for the causality assessment process. It 
should be noted that some of the subjects included in this paper have been included in 
previous papers published by the DILIN. The liver histology findings from most of the 
patients contained in this paper who had a liver biopsy during their liver injury episode have 
been previously described (14) and thus are not included in this report.
Severity Assessment
Laboratory and clinical data were used to assign a disease severity score. Severity was 
scored as mild (1+) for serum enzyme elevations in the absence of jaundice (bilirubin < 2.5 
mg/dL); moderate (2+) by jaundice (bilirubin ≥ 2.5 mg/dL) or coagulopathy (INR >1.5) 
without the need for hospitalization; moderately severe (3+) by jaundice or coagulopathy 
and need for hospitalization; severe (4+) by jaundice and signs of hepatic or other organ 
failure; and fatal (5+) by death from liver disease or the need for liver transplantation within 
six months of onset.
Causality Assessment
The causal relationship between the liver injury and the implicated drug or HDS was 
evaluated in a formal and standardized fashion by the DILIN Causality Committee as 
previously described (10). Causality was assessed as either definite (>95% likelihood), 
highly likely (75–95%), probable (50–74%), possible (25–49%) or unlikely (<25%). In 
cases in which several agents were considered possibly implicated, the overall event was 
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adjudicated for the likelihood that it was DILI, and then each agent was given a separate 
score, but only one agent was permitted to be considered as being highly likely or definitely 
responsible. Cases involving HDS products were often complex, in that multiple products 
were used and the components in the products were often varied and their concentration and 
nature were not always well defined. For this reason, HDS products (even when several 
were being taken) were adjudicated as a single agent at the time of this manuscript 
preparation. Agreement among the reviewers was achieved through email communications 
and teleconferences. Only cases of confirmed DILI (i.e. probable, highly likely or definite) 
were included in this report. The causality assessment for each case occurred 6 months after 
their enrollment which provided an opportunity to follow each case wherever possible for 6 
months and this permitted better characterization of the relationship between the implicated 
agent and the liver injury event.
Assessment of Clinical Patterns of Liver Injury
Assessing the pattern of liver injury as hepatocellular, cholestatic, or mixed is based on 
calculating the “R” ratio, defined by the ratio of serum ALT to Alk P, both expressed as 
multiples of the ULN. By convention, an R ratio of >5 indicates hepatocellular, <2 
cholestatic, and 2–5 mixed injury (16, 17). The R ratio applied to each case was calculated 
based upon values at the onset of injury. In this study we also evaluated a modified R-ratio 
which was based on peak serum ALT and Alk P values, rather than their values at 
presentation.
Data Management and Statistical Analyses
Demographic and clinical data for subjects enrolled into the DILIN Prospective Study 
between September 2004 and May 2013 were extracted on May 16, 2013. Descriptive 
statistics such as means with standard deviation, median with interquartile ratios and 
frequency distributions were used to describe the cohort. Between group difference were 
tested using the chi-square test for categorical variables and Wilcoxon/Kruskal-Wallis test 
for the continuous variables. All statistical analyses were performed using SAS version 9.2 
(SAS Institute, Inc, Cary, NC). A p-value <0.05 was considered statistically significant.
RESULTS
Summary Description of Subjects Enrolled and their Outcomes
Between September 1, 2004 and May 16, 2013, 1257 subjects were enrolled into the DILIN 
Prospective Study. Among these, 1091 had been reviewed and adjudicated by a panel of 
expert hepatologists at the time of these analyses. The scores for likelihood of causality were 
definite in 235 (22%); highly likely in 466 (43%), probable in 198 (18%), possible in 142 
(13%) and unlikely in 50 (5%). The common etiologies for liver injury among these 50 
cases deemed as unlikely due to DILI are flare up of underlying liver disease due to hepatitis 
B or C, autoimmune hepatitis, unsuspected biliary obstruction, and multifactorial (e.g., 
multiple medication, sepsis, and transfusions), especially in those who were hospitalized. 
This analysis is limited to the 899 subjects with causality scores of definite, highly likely, or 
probable.
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Among the 899 subjects with confirmed DILI, 56 (6%) died within 6 months of onset of 
whom 27 (48%) were considered to have died from liver failure related to the drug-induced 
injury. An additional 33 patients underwent liver transplantation (4%) within six months of 
onset. Thus, 10% of the subjects had a fatal outcome that was considered related to the DILI 
event. And additional 126 [17.5%] subjects had evidence of continuing liver injury after 6 
months [subsequently termed “chronic DILI”]. Thus, almost a quarter of patients with DILI 
either died, underwent liver transplant or had residual liver injury at the time of six month 
follow up after onset.
Demographic and selected clinical information for the 899 subjects studied—comparisons 
by their pattern of liver injury
As shown in Table 1, the pattern of liver injury was hepatocellular in 54%, and cholestatic 
or mixed in 23% each. Patients with hepatocellular DILI tended to be younger (p < 0.001), 
less likely to be clinically jaundiced, and to have higher ALT levels than patients with 
cholestatic or mixed injury. In addition, women were relatively over-represented in the 
hepatocellular cohort (65%) compared to the cholestatic or mixed group (51%). The so-
called ‘latency’, that is the time from start of the implicated drug to the time of identification 
of abnormality laboratory tests was significantly longer in hepatocellular cases (median = 46 
vs 31 days, p < 0.001). Immuno-allergic features (at least two of the three features of fever, 
rash, or absolute eosinophilia>500µL) were more frequent in cholestatic (16%) and mixed 
injury (18%) than hepatocellular cases (11%).
The time course of injury was significantly more protracted in cholestatic than in the mixed 
or hepatocellular cases. The distribution of DILI severity scores was dichotomous, in that 
hepatocellular cases had higher proportions that were mild (ALT elevations without 
jaundice) but also a higher frequency of fatal cases (liver related death or transplantation) 
than cases with the cholestatic or mixed injury patterns. Strikingly, patients classified as 
having mixed injury had milder disease overall with fewer liver-related deaths and no cases 
undergoing liver transplantation. While 18% of all patients had evidence of chronic or 
unresolved injury six months after onset (chronic DILI), this outcome was much more 
frequent among cholestatic cases (31%) than either hepatocellular (13%) or mixed-injury 
cases (14%). Thus, the pattern of liver injury at the onset of the clinical syndrome had 
implications for disease severity and outcome with hepatocellular cases more likely to be 
fatal but cholestatic cases more likely to be prolonged and result in chronic injury. Cases of 
mixed injury had the most favorable prognosis and outcomes.
Most frequently implicated classes of drugs and most frequently implicated individual 
drugs
The 899 cases were ultimately attributed to one or more of 190 different agents, including 
145 due to HDS and 754 due to prescription drugs. A total of 189 prescription drugs were 
primary implicated agents for these 754 cases (Supplementary table 1). Antimicrobials were 
by far the most common class of causative drugs, accounting for 408 [45%] instances (Table 
2). Indeed, among individual agents, the nine most commonly implicated agents were all 
antimicrobials, mostly antibiotics (Table 2). Of importance, herbal agents/dietary 
supplements [HDS] were the second most common group but only rare specific HDS agents 
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were implicated more than once and none were in the top 25 implicated agents (data not 
shown). Other therapeutic classes of agents included cardiovascular drugs (88: 10%), central 
nervous system agents (82: 9%), antineoplastic drugs (49: 5%) and analgesics (33: 3%, 
largely nonsteroidal anti-inflammatory agents). A more detailed analysis of the spectrum of 
HDS products that cause liver injury in this cohort as well as the secular trends in HDS-
related liver injury is described in greater detail elsewhere (17). Between initiation of the 
DILIN Prospective Study in 2004 and the most recent years of accrual of patients, the 
proportion of cases attributed to HDS has risen from approximately 7% to 17%.
A listing of all prescription drugs that were implicated as either definite, highly likely or 
probable in at least one DILI case is given in Supplementary Table 1. The ten most 
commonly implicated non-HDS agents accounted for 25% of all cases and the 25 most 
common non-HDS agents accounted for half of all cases. The remaining half of cases were 
caused by agents implicated in only 1 or 2 cases. These results demonstrate the diversity of 
causes of DILI.
Comparisons among most frequent classes of agents and single agents
Among the five most frequent classes of prescription drugs (antimicrobials, cardiovascular 
agents, CNS agents, antineoplastic agents, analgesics), there were few clinical differences in 
the liver injury attributed to their use (Table 3). Most of the differences were attributable to 
differences in the types of patients who would receive these agents. Thus, those with liver 
injury from CNS agents were younger than subjects in the other cohorts (the major agents 
being anticonvulsants and antipsychotic medications). Not surprisingly, those with DILI due 
to anti-neoplastic agents were more likely to die within 12 months of onset and none 
underwent liver transplantation. Similarly, analyses of selected characteristics of DILI for 
the ten most frequent prescription drugs, also showed few notable differences (Supplemental 
Table 2). There were higher frequencies of increased eosinophil counts in DILI due to 
trimethoprim-sulfamethoxazole (31%), cefazolin (30%), ciprofloxacin (33%), all of which 
are known frequently to cause immuno-allergic liver injury (2). There also were higher 
frequencies of high-titer ANA positivity in nitrofurantoin (52%) and minocycline (57%)-
induced DILI; both of these drugs are well known to trigger auto-immune hepatitis in 
susceptible persons (2). For other agents, ANA, when positive, had low titers and with 
frequencies similar to that observed in adult US population (18). DILI due to analgesics was 
usually hepatocellular in nature; for example all 12 cases of diclofenac DILI were 
hepatocellular. Among the cases of analgesic DILI, there was only one death and no one 
required liver transplantation.
Pattern of liver injury according to a modified definition
The R-ratio which biochemically characterizes DILI is typically defined based on ALT and 
Alk P values at the time of onset. However, some patients present with a hepatocellular 
pattern of injury, but subsequently developed marked cholestasis. We therefore sought to 
assess the significance of using an R-ratio based on the peak ALT and peak Alk P values, 
which are often non-concurrent. According to this modified R-ratio, the proportion of 
hepatocellular (52%), cholestatic (25%) and mixed DILI (23%) were largely unchanged. 
Furthermore, the clinical and biochemical characteristics and outcomes of hepatocellular, 
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cholestatic and mixed DILI were not different between two definitions of the R-ratio (data 
not shown). Using the modified R-ratio, 5 cholestatic cases were reclassified as 
hepatocellular, and 8 originally hepatocellular cases were reclassified as cholestatic.
Selected characteristics among the elderly (≥ 65 years) compared to younger subjects (< 
65 years)
The demographic and clinical features of DILI were generally similar in older and younger 
participants (Table 4). The most striking differences were the higher proportion of 
cholestatic pattern of injury among the elderly (36% vs 21%, p < 0.001) with significantly 
higher levels of serum Alk P (at onset, mean, 410 vs 264; at peak 520 vs 383 U/L, p for both 
< 0.001). The severity of liver injury was somewhat lower in the elderly group (p=0.08) as 
was the frequency of chronic DILI (11% vs 19%, p =0.04).
Nine subjects with severe cutaneous adverse reactions
As summarized in Table 5, six subjects exhibited features of Stevens Johnson Syndrome 
(SJS) and 3 had toxic epidermal necrolysis (TEN) (1%). The implicated agents were 
lamotrigine (n=2), azithromycin (n=2), carbamazepine (n=1), moxifloxacin [1], cephalexin 
(n=1), diclofenac (n=1), and nitrofurantoin [1]. The pattern of liver injury was hepatocellular 
in 7 and mixed in 2 patients. In keeping with the known high severity of illness in SJS, four 
of the nine individuals died and an additional individual developed chronic injury, in a 
pattern suggestive of vanishing bile duct syndrome.
DILI in underlying liver disease
Eighty-nine [10%) subjects with DILI had known pre-existing chronic liver disease, mainly 
hepatitis C (n=36) and nonalcoholic fatty liver disease or unexplained elevations in liver 
biochemistries (n=47). Demographic and clinical features of this cohort were generally 
similar to those of patients without known underlying chronic liver disease (Table 6). There 
were no significant differences in the classes of agents to cause DILI in the pre-existing liver 
group (p=0.2) and the top 5 classes of agents were antimicrobials (51%), HDS (13.5%), 
cardiovascular agents (7%), antineoplastic agents (6%) and CNS agents (4.5%). A full 
listing of all implicated agents in individuals with underlying chronic liver disease is shown 
in Supplemental Table 3. Commonly implicated agents were isoniazid (n=7), azithromycin 
(n=6), amoxicillin-clavulanate (n=4) and nitrofurantoin (n=4). Interestingly, azithromycin 
was the implicated agent in a higher proportion of patients with pre-existing liver disease 
compared to those without liver disease (6.7% vs. 1.5%, p=0.006). Individuals with pre-
existing liver disease also had a higher prevalence of diabetes [38% vs 23%, p = 0.004]. 
There was a trend for levels of serum ALT and Alk P to be lower in those with pre-existing 
liver disease, but serum total bilirubin and INR were not different. There were differences in 
the causality scores with fewer cases of definite DILI in individuals with pre-existing liver 
disease (p=0.009). Severity of the liver injury tended to be higher in those with pre-existing 
liver disease but this did not reach statistical significance (p=0.09). Importantly, there was 
higher mortality in those with pre-existing liver disease [16% vs 5.2%, p < 0.001].
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Short (≤ 7 days) vs long latency DILI (> 365 days)
We examined whether there were differences between subjects and their clinical courses, 
depending upon the ‘latency’, the number of days between the start of the causative 
medication and onset of laboratory evidence of DILI (Table 7). There were 41 short-latency 
DILI cases (4.5%) and the most commonly implicated agents were moxifloxacin (n=4), 
azithromycin (n=3), ciprofloxacin (n=3), rifampin (n=2), and levofloxacin (n=2). However, 
there were 60 cases with long latency (6.7%) and the most commonly implicated agents 
were nitrofurantoin (n=16), minocycline (n=10), statins (n=4), amiodarone (n=3), 
mercaptopurine (n=3), atomoxetine (n=2), tamoxifen (n=2), oxaliplatin (n=2) and interferon-
beta (n=2). The frequencies of different patterns of liver injury and profile of liver 
biochemistries were not different between the two groups. There were trends for slower 
resolution of DILI and a trend toward higher likelihood of chronic DILI in those with long 
latency (31% vs 12.5%, p= 0.07) but the rates of death or liver transplantation were not 
different.
DISCUSSION
The DILIN Prospective Study initiated in 2004 has resulted in several important papers 
published previously. These include the characteristics of initial 300 patients enrolled (11), 
natural history of DILI (15) liver histology of DILI (14), DILI in children (20), DILI caused 
by intravenous agents (21), and DILI caused by selected agents (e.g., duloxetine (22), 
flavocoxid (13), interferon-beta (23), quinolones(24). The current paper with by far the 
largest number of prospectively characterized cases of DILI reports several findings which 
have not been reported previously in the literature.
Some novel aspects of this report are description of DILI (a) in the elderly, (b) occurring in 
individuals with underlying chronic liver disease, (c) with very short and long latency, and 
(d) associated severe cutaneous reactions. In addition, it describes temporal trends in the 
causative agents of DILI over the last decade and also provides a detailed comparison of 
characteristics of DILI caused by most common therapeutic classes and individual agents.
Older age is not necessarily a risk factor for all-cause DILI but elderly individuals may be 
higher risk for DILI caused by specific compounds such as amoxicillin-clavulanate (25), 
isoniazid (26,27) and nitrofurantoin (28). Furthermore, it previously has been described that 
cholestatic DILI is more common in the elderly whereas younger individuals are more likely 
to present with hepatocellular DILI (29). This study consisting of a large number of 
individuals who are ≥ 65 years of age indeed confirms that the pattern of their liver injury is 
more likely to be cholestatic than in individuals who are < 65 years of age. It is unclear if 
there is a biological basis for such a difference in the phenotype or if it is a reflection of 
causative agents for DILI in the elderly. In fact, there is significantly highly representation 
of antimicrobials in the elderly individuals (57.5% vs. 43%, p=0.047) and antimicrobials 
such as amoxicillin-clavulanate are known to predominantly cause cholestatic DILI. 
Although there was more cholestatic DILI which is generally associated with higher 
likelihood of chronic DILI, the frequency of chronic DILI in the elderly in this cohort was 
significantly lower than in those who are < 65 years of age. This may in part be due to lower 
prevalence of DILI caused by anabolic steroids in the elderly group which are known to 
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cause prolonger cholestasis and higher likelihood of chronic DILI. Despite their older age 
and polypharmacy, elderly group did not have higher frequency of liver transplantation or 
death.
Some patients with DILI are known to present with severe cutaneous reactions such as SJS 
and TEN but its causative agents and clinical characteristics are not well defined. The 1% 
prevalence of SJS/TEN in this cohort is significantly lower than 7.7% prevalence in 
pediatric DILI reported from India (30). In this report from India, out of 39 children with 
DILI, three developed SJS/TEN due to phenytoin (n=2) and carbamazepine (n=1). 
Interestingly, there were no instances of SJS or TEN among 96 cases of DILI reportedly 
recently from Iceland (5) (Personal communication, Prof. Einar Bjornsson, Reykjavik, 
Iceland). In our experience, lamotrigine and azithromycin were the two common causes of 
DILI with severe skin adverse reactions, with a frequency of 22% for lamotrigine DILI (2 
out of 9 definite/highly likely/probable lamotrigine DILI cases) and 11% for azithromycin 
DILI (2 out of 18 definite/highly likely/probably azithromycin DILI cases). Drugs 
commonly described as at risk for causing severe cutaneous drug reactions are nevirapine, 
lamotrigine, carbamapezine, phenytoin, phenobarbital, trimethoprim-sulfamethaxozole and 
another anti-infective sulfonamides, allopurinol, oxicam NSAIDs, aminopencillins, 
cephalosporins and quinolones (31). Mortality rate for SJS/TEN in our series was 44% with 
3 out of 4 deaths occurring during the acute episode whereas one 10 year old child who 
developed bronchiolitis obliterans and died subsequently due to respiratory failure. The high 
mortality rate observed in this series is generally consistent with 25–30% mortality rate 
described for severe cutaneous adverse reactions (32).
It has been stated that patients with chronic liver disease and cirrhosis are not necessarily at 
risk for all-cause DILI, but it is likely that when an event of DILI occurs they may be at 
higher risk for adverse outcomes such as liver failure or death (33). However, a systematic 
evaluation of etiologic agents, clinical characteristics and outcomes of DILI in individuals 
with preexisting chronic liver disease has been lacking. We found no enrichment of any 
particular therapeutic class in the liver disease group but interestingly there was significant 
enrichment of azithromycin DILI in individuals with preexisting chronic liver disease. It is 
unclear if individuals with underlying liver disease are at higher risk for DILI due to 
azithromycin or this phenomenon is merely a reflection of its higher usage in this patient 
population due to its presumed safety. It is noteworthy that we did not find higher 
prevalence of INH DILI in the liver disease cohort (6.7% in liver disease vs 5.2% in the non-
liver disease group, p=0.5) but this could reflect lower usage of INH in individuals with 
preexisting liver disease. Higher mortality rate noted in the liver disease group supports the 
existing dictum that DILI events in individuals with chronic liver disease leads to higher 
adverse outcomes.
It is noteworthy that individuals who were ≥ 65 years of age had significantly higher 
incidence of Hy’s law and yet their mortality was not significantly different from those who 
were under 65 years ago. The reason for discrepancy is unclear but we observed a similar 
pattern with DILI suspected due to diclofenac where there was 42% incidence of Hy’s law 
and yet there were no deaths attributable to liver injury. This raises the possibility that the 
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relationship between Hy’s law and mortality due to hepatocellular DILI may depend on the 
compound implicated. More work is needed in this area to further clarify this issue.
There are many examples in the literature of instances of DILI occurring either with short 
(<7 days) or after long (>6–12 months) latency but a systematic evaluation of etiologic 
agents and characteristics of DILI with short and long latency has previously not been 
conducted. Contrary to our expectation, there was not significantly higher frequency of 
hypersensitivity features among DILI cases with short latency but 2 out of 9 DILI cases with 
SJS/TEN had short latency (Table 5). Although nitrofurantoin and minocycline are the two 
dominant causes of DILI with long latency, a number of other medications such as 6-
mercaptopurine, statins and amiodarone are also associated with DILI after prolonged 
latency. The knowledge that sometimes DILI can occur after long latency may prevent the 
clinicians from missing a diagnosis of DILI with catastrophic consequences.
An observation that we made in our initial report in 2008 about relatively lower frequency of 
serious adverse outcomes in mixed DILI continues to hold true in this paper (11). The 5.4% 
frequency of death and transplantation in individuals with mixed DILI was lower than 
11.6% and 11.9% frequency of death and transplantation in individuals with hepatocellular 
and cholestatic DILI respectively.
Limitations of our study include inherent selection bias, arbitrary laboratory eligibility 
criteria and lack of established standards for diagnosing DILI. The biochemical criteria we 
used in this study are largely consistent with recent case definitions proposed by an 
international panel of experts. DILI is a diagnosis of exclusion based on appropriate clinical 
history of medication exposure and thorough work up for competing etiologies. Each case 
was carefully and consistently adjudicated in a structured fashion by experienced 
hepatologists (10). Since our study is not population based, one needs to exercise cautious in 
interpreting the reported temporal trends of HDS DILI. Higher representation of HDS during 
later years of our study may simply be a function of higher capture rather than higher 
incidence of HDS DILI.
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Refer to Web version on PubMed Central for supplementary material.
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Table 4
Selected characteristics among the elderly (≥65yo), compared to younger subjects (≤65yo)
≥ 65 years
(n=149)
< 65 years
(n=750)
P value
Age (years, mean [SD]) 73 [6] 44 [14]
Females (%) 60 59 0.8
Self-reported race (%) 0.12
  White 85 77
  Black or African-American 7 13
  Other/Multiracial 8 10
BMI (kg/m2, mean [SD]) 27 [5] 28 [6.8] 0.4
Prior drug allergies (%) 54 42 0.015
Preexisting Liver Disease (%) 10.1 9.9 0.9
Concomitant medicines (%)
  0–2 / 3–5 / >5 16/26/58 26/26/48 0.03
Diabetes mellitus (%) 30 24 0.1
Top 5 implicated classes of agents (%) Antimicrobials (57.7%) Antimicrobials (43%) <0.001
Cardiovascular (14.8%) HDS (17.7%)
HDS (8.1%) CNS agents (10.4%)
Antineoplastic (4%) Cardiovascular (8.8%)
Analgesics (3.4%) Antineoplastic (5.7%)
Latency (days in median , IQR) 35 [18–99] 36 [19–84] 0.8
Jaundice (%) 67 71 0.4
Pattern of liver injury
  HC/Chol/Mixed (%) 39/36/25 57/21/22 <0.001
Liver Biochemistries –DILI recognition
  ALT (U/L, mean [SD]) 619.5 [860.5] 866± [1143.5] 0.007
  AP (U/L, mean [SD]) 410 [361] 264 [220] <0.001
  Total bilirubin (mg/dl, mean [SD]) 7.0 [6.7] 6.6 [6.6] 0.4
  INR 1.6 [1.2] 1.4 [0.9] 0.9
Hy’s law (%) 18 32 0.001
Liver Biochemistries – Peak values
  ALT (U/L, mean [SD]) 757 [911] 1057 [1268] 0.002
  AP (U/L, mean [SD]) 520 [446] 383 [372] <0.001
  Total bilirubin (mg/dl, mean [SD]) 14 [12] 13 [12] 0.4
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≥ 65 years
(n=149)
< 65 years
(n=750)
P value
  INR 1.8 [1.65] 1.7 [1.5] 0.9
Peripheral eosinophilia (>500/µL) (%) 11 11 1.0
Improvement in biochemistries – days in
median
  - Peak ALT to below ULN 62 74 0.5
  - Peal AP to below ULN 106 90 0.5
  - Peak bilirubin to ≤ 1 mg/dL 78 68 0.8
Causality Assessment (%)
Definite/ Highly likely/ Probable 25.5/55/19.5 26/51/23 0.6
Severity of Liver Injury (%)
  Mild 31 22 0.08
  Moderate 19.5 22
  Moderate-hospitalized 29 29.5
  Severe 13 20
  Fatal 8 6.7
Death, at any time point (%) 8.7 5.7 0.2
  - Proportion of Liver –related (%) 54 48 0.8
Liver Transplantation (%) 2 4.4 0.25
Chronic DILI (%) 11.4 18.7 0.04
Abbreviations used: ALT, serum alanine aminotransferase; AP, serum alkaline phosphatase; BMI, body mass index; Chol, cholestatic; DILI, drug-
induced liver injury; HC, hepatocellular; INR, international normalized ratio; IQR, interquartile range (25–75%); SD, standard deviation; ULN, 
upper limit of normal
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Table 6
DILI in Subjects with and without Known Pre-existent Liver Disease
Known pre-existent
liver disease
(n=89)
No known pre
existent liver
disease
(n=810)
P value
Age (years, mean ± SD) 52± 12.4 48 ±17.4 0.08
Females (%) 54 59 0.4
Self-reported race (%) 0.35
  White 73 79
  Black or African-American 13.5 11.5
  Other/Multiracial 13.5 9
BMI (kg/m2, mean ± SD) 28± 6.9 27 ± 6.5 0.72
Prior drug allergies (%) 46 44 0.7
Diabetes mellitus (%) 38 23 0.004
Top 5 implicated classes of agents (%) Antimicrobials (51%) Antimicrobials (45%) 0.2
HDS (13.5%) HDS (16%)
Cardiovascular (6.7%) Cardiovascular (10.1%)
Antineoplastic (6%) CNS agents (9.6%)
CNS agents (4.5%) Antineoplastic (5.4%)
Latency (days in median , IQR) 34 (20–63) 36 (19–89) 0.3
Jaundice (%) 70 70 0.9
Pattern of liver injury
  HC/Chol/Mixed (%) 54/31/15 54/22/24 0.058
Liver Biochemistries –DILI recognition
  ALT (U/L, mean± SD) 689± 1037 840± 1112 0.12
  AP (U/L, mean± SD) 284± 310 289± 248 0.11
  Total bilirubin (mg/dl, mean± SD) 7.4± 7.0 6.6± 6.6 0.3
  INR 1.6± 0.9 1.4± 1.0 0.2
Hy’s law (%) 31 29 0.8
Liver Biochemistries – Peak values
  ALT (U/L, mean± SD) 821 ± 1086 1028± 1234 0.08
  AP (U/L, mean± SD) 380± 458 408± 380 0.02
  Total bilirubin (mg/dL, mean± SD) 13± 11.4 13± 12 0.8
  INR 1.8± 1.6 1.7± 1. 5 0.12
Peripheral eosinophilia (>500/µL) (%) 12 11 0.7
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Known pre-existent
liver disease
(n=89)
No known pre
existent liver
disease
(n=810)
P value
Improvement in biochemistries – days in
medianPeak ALT to below ULN
  - Peal AP to below ULN 64 73 0.3
  - Peak bilirubin to ≤ 1 mg/dL 139 93 0.5
64 70 0.5
Causality Assessment (%)
Definite/ Highly likely/ Probable 17/49/34 27/52/21 0.009
Severity of Liver Injury (% of column total)
  Mild 29 23 0.09
  Moderate 15 22
  Moderate-hospitalized 27 30
  Severe 17 19
  Fatal 12.4 6.3
Death, at any time point (%) 16 5.2 <0.001
  - Percent Liver –related 57 46 0.5
Liver Transplantation (%) 3.4 4.1 1.0
Chronic DILI (%) 13.7 17.9 0.4
Abbreviations: ALT, serum alanine aminotransferase; AP, serum alkaline phosphatase; BMI, body mass index; Chol, Cholestatic; DILI, drug-
induced liver injury; HC, hepatocellular; INR, international normalized ratio; IQR, interquartile range (25–75%); SD, standard deviation; ULN, 
upper limit of normal
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Table 7
Comparison of Subjects with Short vs. Long Latency DILI
Short latency (≤ 7
days)
(n=41)
Long latency
(>365 days)
(n=60)
P value
Age (years, mean ± SD) 49± 17 50±22 0.5
Females (%) 56 70 0.2
Self-reported race (%) 0.2
  White 82.5 93
  Black or African-American 7.5 3
  Other/Multiracial 10 3
BMI (kg/m2, mean ± SD) 27± 6.9 27.3 ± 6.7 0.9
Prior drug allergies (%) 46 55 0.4
Diabetes mellitus (%) 24 28 0.8
Preexisting liver disease (%) 14.6 3.3 0.06
Top 5 implicated classes of agents Antimicrobials (71%) Antimicrobials (45%) 0.03
HDS (7%)* Antineoplastic (15%)
Analgesics (5%) Cardiovascular (13%)
Immunomodulatory (5%) CNS agents (12%)
CNS or cardiovascular or
Endocrine or GI or
hematological agents (2%)
Immunomodulatory (6.7%)
Latency (days in median , IQR) 5 (3–7) 643 (483–1297) <0.001
Jaundice (%) 58.5 53 0.7
Hypersensitivity features (%)
  • Fever 27 13 0.1
  • Itching 29 40 0.3
  • Rash 22 20 0.8
  • SJS 0 0
Pattern of liver injury
  HC/Chol/Mixed (%) 49/22/29 57/30/13 0.14
Liver Tests –at DILI recognition
  ALT (U/L, mean± SD) 831 ± 1500 712± 725 0.9
  AP (U/L, mean± SD) 244± 145.6 290± 251 0.8
  Total bilirubin (mg/dL, mean± SD) 4.1±4.3 6.1± 7.4 0.6
  INR 1.5± 0.9 1.5± 0.8 0.3
Hy’s law (%) 17.5 17 1.0
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Short latency (≤ 7
days)
(n=41)
Long latency
(>365 days)
(n=60)
P value
Liver Tests – Peak values
  ALT (U/L, mean± SD) 1008± 1648 863± 791344±338 0.6
  AP (U/L, mean± SD) 335± 234.5 8.9±9.3 0.6
  Total bilirubin (mg/dL, mean± SD) 8± 9.2 1.8± 1.9 0.8
  INR 1.8± 1.7 0.5
Peripheral eosinophilia (>500/µL)
(%)
7.7 8.6 1.0
Improvement in liver tests –median
d
  - Peak ALT to below ULN 68 98 0.07
  - Peal AP to below ULN 84 129 0.99
  - Peak total bilirubin to ≤ 1 mg/dL 36 76 0.3
mg/dL
Causality Assessment
  Definite/ Highly likely/ Probable 10/54/37 15/62/23 0.3
Severity of Liver Injury (%)
  Mild 32 37 0.17
  Moderate 27 15
  Moderate-hospitalized 22 12
  Severe 12 28
  Fatal 7.3 8.3
Death, at any time point (%) 4.9 13.3 0.2
  -Percent Liver –related 50 71 1.0
Liver Transplantation (%) 2.4 3.3 1.0
Chronic DILI (%) 12.5 31 0.07
Causative agents Moxifloxacin (4)
Azithromycin (3)
Ciprofloxacin (3)
HDS (3)
Rifampicin (2)
Levofloxacin (2)
Nitrofurantoin (1),
Azathioprine (1), Amoxicillin (1),
Amox-clavulanate (1),
Antithymocyte globulin (1),
Cefaclor (1), Cefazolin (1),
Cefotaxime (1), Ceftriaxone
(1), Dalteparin (1), Diclofenac (1),
Erythromycin (1),
Fluconazole (1), Meropenam (1),
Methylprednisolone (1),
Micafungin (1), Nicotinic acid (1),
Oxaprozin (1), Phenytoin (1),
Piperacillin-tazobactam (1),
Ranitidine (1), TMP-SMX
(1), Telithromycin (1),
Nitrofurantoin (16)
Minocycline (10)
Amiodarone (3)
Mercaptopurine (3)
Atomoxetine (2)
Atorvastatin (2)
Rosuvastatin (2)
Tamoxifen (2)
Oxaliplatin (2)
Buproprion (2), Nicotinic acid (1),
Azathioprine (1),
Diclofenac (1), Etravirine (1),
Imatinib (1), Interferon-beta(2),
Fluoxetine (1), Metformin (1),
Methotrexate (1),
Methylphenidate (1),
Promethazine (1), Tacrolimus(1),
Testosterone (1),
Topiramate (1), HDS (1)
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Short latency (≤ 7
days)
(n=41)
Long latency
(>365 days)
(n=60)
P value
Vancomycin (1)
Abbreviations: ALT, serum alanine aminotransferase; AP, serum alkaline phosphatase; BMI, body mass index; Chol, Cholestatic; DILI, drug-
induced liver injury; HC, hepatocellular; INR, international normalized ratio; IQR, interquartile range; SD, standard deviation; AMX, 
sulfamethoxazole; TMP, trimethoprim; ULN, upper limit of normal.
*
Implicated HDS agents in 3 cases with short latency were (a) multiple CAM products - Extenze, AMP muscle building formula; (2) Multiple 
CAM products – Bulgarian mushrooms, Aloe Vera, Boldo tea; and (3) Meganite
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